Mark Everard

Prof. Mark Everard


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2008 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
Anne B. ChangAnne B. Chang
Anne B. Chang
GRG.J. Redding
G.J. Redding
MEMark Everard
Mark Everard

18 July 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
CWColin Wallis
Colin Wallis
EAEfthymia Alexopoulou
Efthymia Alexopoulou
JAJuan L. Antón-Pacheco
Juan L. Antón-Pacheco
JBJayesh M. Bhatt
Jayesh M. Bhatt
ABAndrew Bush
Andrew Bush
KPKostas Priftis
Kostas Priftis
Tracheomalacia and tracheobronchomalacia may be primary abnormalities of the large airways or associated with a wide variety of congenital and acquired conditions. The evidence on diagnosis, classification and management is scant. There is no universally accepted classification of severity. Clinical presentation includes early-onset stridor or fixed wheeze, recurrent infections, brassy cough and even near-death attacks, depending on the site and severity of the lesion. Diagnosis is usually made by flexible bronchoscopy in a free-breathing child but may also be shown by other dynamic imaging techniques such as low-contrast volume bronchography, computed tomography or magnetic resonance imaging. Lung function testing can provide supportive evidence but is not diagnostic. Management may be medical or surgical, depending on the nature and severity of the lesions, but the evidence base for any therapy is limited. While medical options that include bronchodilators, anti-muscarinic agents, mucolytics and antibiotics (as well as treatment of comorbidities and associated conditions) are used, there is currently little evidence for benefit. Chest physiotherapy is commonly prescribed, but the evidence base is poor. When symptoms are severe, surgical options include aortopexy or posterior tracheopexy, tracheal resection of short affected segments, internal stents and external airway splinting. If respiratory support is needed, continuous positive airway pressure is the most commonly used modality eitherviaa face mask or tracheostomy. Parents of children with tracheobronchomalacia report diagnostic delays and anxieties about how to manage their child's condition, and want more information. There is a need for more research to establish an evidence base for malacia. This European Respiratory Society statement provides a review of the current literature to inform future study.

24 August 2017 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
Ahmad KantarAhmad Kantar
Ahmad Kantar
Anne B. ChangAnne B. Chang
Anne B. Chang
MSMike D. Shields
Mike D. Shields
Julie M. MarchantJulie M. Marchant
Julie M. Marchant
KGKeith Grimwood
Keith Grimwood
MEMark Everard
Mark Everard
This European Respiratory Society statement provides a comprehensive overview on protracted bacterial bronchitis (PBB) in children. A task force of experts, consisting of clinicians from Europe and Australia who manage children with PBB determined the overall scope of this statement through consensus. Systematic reviews addressing key questions were undertaken, diagrams in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement constructed and findings of relevant studies summarised. The final content of this statement was agreed upon by all members.The current knowledge regarding PBB is presented, including the definition, microbiology data, known pathobiology, bronchoalveolar lavage findings and treatment strategies to manage these children. Evidence for the definition of PBB was sought specifically and presented. In addition, the task force identified several major clinical areas in PBB requiring further research, including collecting more prospective data to better identify the disease burden within the community, determining its natural history, a better understanding of the underlying disease mechanisms and how to optimise its treatment, with a particular requirement for randomised controlled trials to be conducted in primary care.

28 September 2007 in Thorax
Verified
Journal Article
Open access
PDF file
MSMichael David Shields
Michael David Shields
ABA Bush
A Bush
MEMark Everard
Mark Everard
SMS McKenzie
S McKenzie
RPR Primhak
R Primhak
OGon behalf of the British Thoracic Society Cough Guideline Group
on behalf of the British Thoracic Society Cough Guideline Group
Community-based surveys show that parental-reported cough as an isolated symptom has a high prevalence.2 3 Reported cough without colds has a prevalence of 28% in boys and 30% in girls.4

1 January 2007 in Thorax
Verified
Journal Article
Open access
PDF file
DDDeirdre Donnelly
Deirdre Donnelly
ACAnita Critchlow
Anita Critchlow
MEMark Everard
Mark Everard
Background: Persistent bacterial bronchitis (PBB) seems to be under-recognised and often misdiagnosed as asthma. In the absence of published data relating to the management and outcomes in this patient group, a review of the outcomes of patients with PBB attending a paediatric respiratory clinic was undertaken. Methods: A retrospective chart review was undertaken of 81 patients in whom a diagnosis of PBB had been made. Diagnosis was based on the standard criterion of a persistent, wet cough for >1 month that resolves with appropriate antibiotic treatment. Results: The most common reason for referral was a persistent cough or difficult asthma. In most of the patients, symptoms started before the age of 2 years, and had been present for >1 year in 59% of patients. At referral, 59% of patients were receiving asthma treatment and 11% antibiotics. Haemophilus influenzae and Streptococcus pneumoniae were the most commonly isolated organisms. Over half of the patients were completely symptom free after two courses of antibiotics. Only 13% of patients required ⩾6 courses of antibiotics. Conclusion: PBB is often misdiagnosed as asthma, although the two conditions may coexist. In addition to eliminating a persistent cough, treatment may also prevent progression to bronchiectasis. Further research relating to both diagnosis and treatment is urgently required.

4 November 2016 in Thorax
Verified
Journal Article
Closed access
PDF file
RMRobert W Morton
Robert W Morton
HEHeather E Elphick
Heather E Elphick
ARAlan S Rigby
Alan S Rigby
WDWilliam J Daw
William J Daw
DKDavid A King
David A King
MEMark Everard
Mark Everard
Background Suboptimal adherence to inhaled steroids is common in children with asthma and is associated with poor disease control, reduced quality of life and even death. Previous studies using feedback of electronically monitored adherence data have demonstrated improved adherence, but have not demonstrated a significant impact on clinical outcomes. The aim of this study was to determine whether introduction of this approach into routine practice would result in improved clinical outcomes. Methods Children with asthma aged 6–16 years were randomised to the active intervention consisting of electronic adherence monitoring with daily reminder alarms together with feedback in the clinic regarding their inhaled corticosteroid (ICS) use or to the usual care arm with adherence monitoring alone. All children had poorly controlled asthma at baseline, taking ICS and long-acting β-agonists. Subjects were seen in routine clinics every 3 months for 1 year. The primary outcome was the Asthma Control Questionnaire (ACQ) score. Secondary outcomes included adherence and markers of asthma morbidity. Results 77 of 90 children completed the study (39 interventions, 38 controls). Adherence in the intervention group was 70% vs 49% in the control group (p≤0.001). There was no significant difference in the change in ACQ, but children in the intervention group required significantly fewer courses of oral steroids (p=0.008) and fewer hospital admissions (p≤0.001). Conclusions The results indicate that electronic adherence monitoring with feedback is likely to be of significant benefit in the routine management of poorly controlled asthmatic subjects. Trial registration number NCT02451709; pre-result.